Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telisotuzumab adizutecan plus pembrolizumab first-line study in recurrent or metastatic head and neck squamous cell carcinoma
jRCT2051260159Phase 2Not yet recruiting
- Sponsor
- AbbVie Inc.
- Start
- Oct 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, open-label trial in head and neck squamous cell carcinoma (HNSCC) comparing Telisotuzumab adizutecan + pembrolizumab with Pembrolizumab + platinum + fluorouracil (2 arms). Primary endpoints: Objective response rate, Progression-free survival and 1 more. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
telisotuzumab adizutecanpembrolizumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on jRCT2051260159.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051260159.